Glycopyrrolate Pediatric Dosing
For children aged 3 years and older, initiate glycopyrrolate oral solution at 0.02 mg/kg three times daily, titrating in increments of 0.02 mg/kg every 5-7 days to a maximum of 0.1 mg/kg three times daily (not exceeding 1.5-3 mg per dose based on weight). 1
Oral Route (Primary Indication: Chronic Severe Drooling)
Dosing Algorithm
Starting dose: 0.02 mg/kg orally three times daily 1
Titration schedule:
- Increase by 0.02 mg/kg every 5-7 days over a 4-week titration period
- Before each dose increase, assess tolerability with the caregiver
- Maximum dose: 0.1 mg/kg three times daily, with absolute maximum of 1.5-3 mg per dose depending on weight 1
Administration timing: Give at least 1 hour before or 2 hours after meals, as high-fat food significantly reduces oral bioavailability 1
Weight-Based Dosing Table
The FDA-approved oral solution provides specific dose levels by weight 1:
- 13-17 kg (27-38 lbs): Start 0.3 mg (1.5 mL) TID, max 1.5 mg (7.5 mL) TID
- 18-22 kg (39-49 lbs): Start 0.4 mg (2 mL) TID, max 2.0 mg (10 mL) TID
- 23-27 kg (50-60 lbs): Start 0.5 mg (2.5 mL) TID, max 2.5 mg (12.5 mL) TID
- ≥48 kg (≥105 lbs): Start 1.0 mg (5 mL) TID, max 3.0 mg (15 mL) TID
Injectable Route (Perioperative/Acute Use)
Preanesthetic Medication
0.004 mg/kg IM, given 30-60 minutes before anesthesia induction 2
- Infants (1 month to 2 years): May require up to 0.009 mg/kg 2
Intraoperative Use
0.004 mg/kg IV (not to exceed 0.1 mg in a single dose), repeated every 2-3 minutes as needed for bradycardia or vagal reflexes 2
Reversal of Neuromuscular Blockade
0.2 mg glycopyrrolate for each 1.0 mg neostigmine or 5.0 mg pyridostigmine, given simultaneously IV 2
Adjunct to Ketamine Sedation
When used to reduce salivation during ketamine procedural sedation, glycopyrrolate 5 mcg/kg IV has been studied 3. The 2008 AAP guideline notes that "atropine or glycopyrrolate may be used to prevent increased salivation" with ketamine 4
Clinical Efficacy Evidence
The oral formulation demonstrates robust efficacy for chronic drooling. In the pivotal Phase III trial, 73.7% of patients achieved a ≥3-point improvement on the modified Teacher's Drooling Scale versus 17.6% with placebo (p=0.0011) 5. A 24-week open-label study showed 52.3% responder rate with sustained benefit 6.
Safety Profile and Common Pitfalls
Most common adverse effects (≥10%):
- Constipation (20%)
- Vomiting (18%)
- Diarrhea (18%)
- Dry mouth (11%)
- Flushing (11%)
- Nasal congestion (11%) 6
Critical monitoring points:
- Assess for constipation within 4-5 days of starting therapy or after dose increases, as this is the most common dose-limiting adverse effect 1
- Approximately 20% of children may experience adverse effects severe enough to require discontinuation 7
- Discontinuation rate due to adverse events: 13.9% in long-term studies 6
Contraindications:
- Glaucoma, paralytic ileus, unstable cardiovascular status, severe ulcerative colitis, myasthenia gravis 1
- Concomitant solid oral potassium chloride (may arrest GI passage) 1
High ambient temperature warning: Avoid exposure to high environmental temperatures due to risk of heat prostration from reduced sweating 1
Age-Specific Considerations
Children under 3 years: The FDA-approved oral solution is not indicated for children under 3 years 1. However, emerging evidence suggests potential safety and efficacy in this population. A 2022 case series of 18 children under 3 years (median age 17 months) showed 94% response rate with mean Drooling Impact Scale improvement from 89 to 61 (p<0.001) 8. If used off-label in this age group, start at the lower end of the dosing range (0.02 mg/kg TID) with close monitoring.
Adolescents: The oral formulation is FDA-approved through age 16 years 1, though studies have included patients up to age 23 5.
Pharmacokinetic Considerations
- Oral bioavailability: Highly variable, median 3.3% 9
- Time to peak: Mean 3.1 hours in children 9
- Half-life: 19-99 minutes in children 9
- Clearance: 0.6-1.43 L/kg/h 9
Renal impairment: Use with caution; dose adjustment may be necessary 1